NCT06494150View on ClinicalTrials.gov

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

September 30, 2029

Conditions
Low Grade Ovarian Serous Adenocarcinoma
Interventions
DRUG

nab-Sirolimus

nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle

DRUG

Fulvestrant

Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days

Trial Locations (1)

73117

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

Sponsors

Collaborators (1)

Aadi Bioscience, Inc.
All Listed Sponsors
collaborator

Aadi Bioscience, Inc.

INDUSTRY

lead

University of Oklahoma

OTHER